About Us

FOR IMMEDIATE RELEASE

 

Sanovas Awarded Seminal Patent for Imaging Stylet for Intubation

 

LightSpeed Intubation System™ offers an evolutionary advance to endotracheal intubation procedures intended to make airway management, safer, faster and easier to perform

 

SAN RAFAEL, Calif., June 29, 2017 -- Sanovas, Inc., a life science asset holding company and medical technology accelerator, announced today that the United States Patent and Trademark Office issued patent # 9,662,466 for the company's Imaging Stylet for Intubation.  

 

There are over 40 million Endotracheal Intubations performed annually in the U.S., making it the single largest interventional procedure. Nearly 2 million of those procedures are complex and challenging to perform. The LightSpeed Intubation System™ enables quicker and safer positioning of the endotracheal tube without losing control of the airway.

 

In critically injured, ill or anesthetized patients, it is often necessary to insert an endotracheal tube into a person's airway to facilitate ventilation of the lungs and to prevent the possibility of asphyxiation or airway obstruction. The most common routes of inserting the endotracheal tube are oral, in which the tube is passed through the mouth and larynx into the trachea, and nasal, wherein the tube is passed through the nose and larynx into the trachea.

 

Sanovas’ subsidiary Intubation Science, Inc. will bring the new technology to market.

"Intubation Science's LightSpeed Intubation System offers a new and improved approach to endotracheal intubation and is intended to make this procedure, safer, faster and easier to perform," said Larry Gerrans, Sanovas CEO and the LSI's co-inventor. "There are a myriad of clinicians who have purview over airway management, from Emergency Medical Technicians (EMT) to Anesthesiologists, and their skills and experience vary widely. The LSI system has been designed to improve procedural accuracy and speed and to make airway management safer and more reproducible for ALL patients and clinicians, every time."

 

The insertion of the endotracheal tube often involves serious risks, such as damage to the vocal cords and a prolonged intubation procedure in which the patients breathing is stopped, but oxygen is not yet delivered to the patient as the tube has not yet been inserted. It is estimated that about one third of deaths occurring during a surgical procedure while under anesthesia for morbidly obese patients are associated with the intubation process. Some of the difficulties that persons performing endotracheal intubation encounter include the restriction of view as the tube is inserted, variations in the anatomy of the patients, an uncomfortable and unnatural position of the person performing the procedure while holding the instrument, and the necessity for rapid intubation.

 

"Current systems can pose challenges to clinicians, especially during difficult cases, as they do not provide sufficient visualization of and navigation to the anatomy," said Dr. Chris Baker who is a Board Certified Physician in Pediatric Emergency Medicine at UCSF Benioff Children's Hospital and the co-designer of the LightSpeed Intubation System. The biggest challenge of the intubation process is to accurately and quickly advance the endotracheal tube (ETT) through the vocal cords without causing damage.  Improper placement can result in injury, delayed care and in some cases, death to the patient."

 

The LightSpeed Intubation System's uni-body, side-loading design saves space, mitigates displacement of soft tissues and enables doctors to facilitate airway placement quickly.

 

The LSI's revolutionary design features an integrated optical stylet with a deflectable tip and steerable stylet in order to better navigate and visualize the anatomy throughout the procedure. The optical stylet gives direct visualization into the trachea confirming that the endotracheal tube clears the vital anatomy of the larynx.  Further, since it is steerable, it ensures the inflation cuff is correctly positioned between the larynx and the carina with precision.  Additionally, the system eliminates the need for costly chest x-rays required to confirm positioning.   An additional feature of LSI is that its optical stylet serves as an ETT 'switching stick' for those ventilated patients who need a tube exchange.

 

"Intubation can be tricky! Traditional systems are bulky and inflexible. They can be difficult to maneuver through narrow anatomy and can cause life threatening complications if the endotracheal is misplaced in the esophagus, which happens. The LightSpeed Intubation System addresses common difficulties of intubation with its integrated, flexible design, visualization and navigation capabilities.  This allows doctors to perform the procedure with precision," said Gerrans.

 

About Intubation Science, Inc.

 

There are over 40 million Endotracheal Intubations performed annually (US) with nearly 2 million being complex and challenging to perform. The company's LightSpeed Intubation System ™, a new and improved solution for Endotracheal Intubation will make this most widely performed of all surgical procedures, safer, faster and easier to achieve.  Intubation Science, Inc. is a subsidiary of Sanovas, Inc.

 

Contact:

 

Steve Goldsmith

This email address is being protected from spambots. You need JavaScript enabled to view it.

415-729-9391 x1023

Company Focus: Redefining Intervention

Sanovas is redefining intervention with access, imaging, and measurement technologies that enable physicians to perform MORE interventional procedures, in MORE places, MORE affordably. The company is dedicated to developing the full continuum of best-in-class minimally invasive diagnostic and therapeutic technologies and solutions that are affordable, accessible, and safe across multiple procedures and specialty areas.

For physicians and their patients around the world, Sanovas interventional technologies will improve access to advanced minimally invasive diagnostic and therapeutic procedures in millions of healthcare facilities and practices:

  • Enabling safe, reliable working access in small and previously inaccessible anatomic spaces.
  • Making visualization and imaging technologies portable, versatile, and more affordable to hospitals and healthcare facilities globally.
  • Enabling advanced local diagnostic and therapeutic interventions throughout the body.
  • Leveraging core platform micro technologies across multiple medical specialties.

In summary, Sanovas is a company solving big healthcare market access, safety, quality, and cost problems while growing the minimally invasive interventions market. Working with physicians and hospital executives, Sanovas is leading the way in making minimally invasive interventions more accessible, affordable, and safe around the world. 

Taking AIM At Making Interventions More Accessible, Affordable, and Safe

Minimally Invasive Surgery (MIS), the ability to perform medical interventions through small “key holes” versus large, open incisions, has flourished over the past 20 years. Now however, the necessity to go farther and do more has created the opportunity for innovation and technology to redefine MIS and to make what is now possible accessible, affordable, and safe for more people.

Sanovas’ core micro technology platform is built on the principal of improving the AIM – Access, Imaging, and Measurement – of physicians performing diagnostic and therapeutic interventions. As a result of our adherence to the AIM principal, our portfolio provides physicians and hospitals with the ability to:

  • Access Accessing remote small diameter and challenging anatomies that were previously inaccessible
  • Imaging Visualizing anatomies in new, innovative ways that enables safe procedures and dramatically reduces the costs associated with endoscopy and procedural visualization
  • Measurement Enabling physicians with the physiologic intelligence of the anatomy and related pathology to understand and control the procedural environment in small anatomic spaces
  • Diagnostics Making diagnostic procedures in challenging anatomies safe and accessible and reducing cost and complexity to expand access to advanced diagnostic procedures for millions of people in healthcare facilities worldwide
  • Therapeutics Providing physicians with ‘patient friendly’ tools to provide advanced local therapies in challenging anatomies and to reduce toxicity and risks associated with conventional surgery or chemical therapies

It is estimated that millions more healthcare providers will be able to affordably offer diagnostic and therapeutic interventions for their communities because of Sanovas’ platform micro technologies. For example, scopes, cameras and other devices made with MicroCam Imaging™ technology are projected to reduce endoscopy costs by up to 80% and eliminate as much as 90% of the associated capital equipment requirements for hospitals and healthcare facilities.

And, Sanovas access, imaging, and measurement technologies will enable physicians to safely perform advanced, multi-instrument and multi-modal diagnostic and therapeutic procedures in previously inaccessible anatomies. These procedures will make localized, interventional treatments for lung cancer and other serious diseases available to millions of people – reducing the need for open surgeries and treatments that create systemic toxicity.

Meeting One Challenge Led To A World Of Solutions

Sanovas’ was founded with the humanitarian inspiration to treat and cure Lung Cancer and related pulmonary diseases. The genesis for this inspiration was rooted in the real life experiences of Sanovas’ Founder, Larry Gerrans, who relates “I watched my teammate in elementary school almost die from an Asthma attack. I can’t remember my grandmother without an oxygen hose in her nose, and she rarely left her house. I lost my best friend’s Mom, who was a surrogate mother to me, to Lung Cancer within days of her diagnosis. I never got the chance to say goodbye to her.”

Through the discovery process of creating the solutions required to diagnose and treat the lungs, it was found that an integrated set of tools and a systems based approach was required. And, the Sanovas team determined that these technologies had application across a range of disease states and medical specialties.

“We learned that the lungs have long been recognized as the last frontier in interventional medicine,” explains Larry. “This is due to the complexity of their small airways, and the fact that they cannot be ‘turned off’ to be repaired. “Consequently, doctors must operate on a live, breathing anatomy. This is analogous to being repelled into the mouth of an angry volcano where you have hot lava (i.e., blood and mucous) spewing at you,” says Larry, “where hot air is rushing at you from below while cold air is coming down from above, creating a foggy atmosphere that is tough to see through. “What’s even worse is that in the small, tight spaces of the bronchioles the airway walls are constantly moving in and out, creating motion artifact that can give the doctor spatial nausea, vertigo and motion sickness,” Larry adds. These lessons learned in developing technologies that will work in the lungs, will have significant application in challenging vasculatures and other tubular anatomies.

“A sick lung is tough terrain and a hostile environment. Regrettably, as a result, most people with complex airways have long been sent home or to hospice. But this is all about to change,” says Larry. “Industry and government are converging on interventional pulmonology, a relatively new field in pulmonary medicine. We are making it a national priority, and we are going to get this right. The impact of chronic non-communicable pulmonary disease on the US GDP is colossal. We are going to lessen that impact…and more.”

Why Interventions Need To Be Redefined

Medical interventions, the ability to access the body without surgery to diagnose and treat, have flourished in the past few decades. Now, however; opportunity and necessity have combined to redefine what is possible through interventions and to make what is possible accessible, affordable, and safe for more people.

It is estimated that millions more healthcare providers will be able to affordably offer diagnostic and therapeutic interventions for their communities because of Sanovas' platform micro technologies. For example: scopes, cameras, and other devices made with MicroCamTM Imaging technology are projected to reduce endoscopy costs by up to 80% and eliminate as much as 90% of the associated capital equipment requirements for hospitals and healthcare facilities.

And, Sanovas access, imaging, and measurement technologies will enable physicians to safely perform advanced, multi-instrument and multi-modal diagnostic and therapeutic procedures in previously inaccessible anatomies. These procedures will make localized, interventional treatments for lung cancer and other serious diseases available to millions of people - reducing the need for open surgeries and treatments that create systemic toxicity.

Core Micro Technologies

The Sanovas product portfolio is built on a platform of core micro technologies. These access, imaging, measurement, diagnostic, and therapeutic technologies have application across multiple products and medical specialties. The Sanovas core micro technologies contribute to making advanced diagnostic and therapeutic interventions accessible, affordable, and safe in small anatomic spaces. These core micro technology platforms are:

  • ViaTM Working Channels
  • VasZeppelinTM Smart Catheters
  • MicroCamTM Imaging Technologies
  • StablePathTM Catheter Anchoring Technology
  • PhysioSenseTM Physiologic Measurement Systems
  • CytoVasTM Tissue Collection Technology
  • NanoVasTM Local Therapy Delivery Systems

Business Units

Sanovas' commercial business is segmented into business units that leverage cost-effective delivery of advanced diagnostic and therapeutic interventions enabled by our core micro technology platforms. Each business unit focuses on a specific target audience. These current business units are

  • Imaging Technologies: Excellent in-situ visualization for unprecedented access to small anatomic spaces, dramatic endoscopy-related cost reductions, and imaging in the non-visible spectrum to enable advanced diagnostic and therapeutic interventions.
  • Interventional Lung: Minimally invasive, localized advanced diagnostic and therapeutic interventions for a range of lung pathologies.
  • Interventional ENT: Minimally invasive, localized, advanced diagnostic and therapeutic interventions for a range of head and neck pathologies.
  • Interventional Uro & Gyn: Minimally invasive, localized, advanced diagnostic and therapeutic interventions for a range of urologic and gynecologic pathologies.
bussiness-logic

News and Events

  • tie
    Sanovas Awarded Global Top 50 Start-up Company

    We are excited to announce that Sanovas, Inc. was recognized as one of the Top 50 Start-Up Companies in the World at the Silicon Valley TiE50 2015 Award ceremony. Read More.

  • tie2
    Sanovas commercializes its breakthrough device-reprocessing product designed to identify poorly cleaned medical devices that could trigger infections

    In wake of recent headlines about cross contamination of patients by inadequately reprocessed medical devices (see story in USA Today), Sanovas Inc., a Life Science company accelerating the development and commercialization of next-generation micro-invasive diagnostics, devices and drugdelivery technologies, announced today that its MicroCam Inc.subsidiary has commenced commercialization of the MicroCamTM System via its OEM partnership with Healthmark Industries, which has launched its new product-Flexible Inspection Scope. Read More.

FDA REGULATORY DISCLOSURE:
Sanovas Inc. is an emerging technology company. These products are investigational medical devices that have not been approved or cleared for use in the United States.